Online citations, reference lists, and bibliographies.
← Back to Search

Folate Receptor Expression In Carcinomas And Normal Tissues Determined By A Quantitative Radioligand Binding Assay.

N. Parker, M. Turk, Elaine Westrick, J. D. Lewis, P. Low, C. P. Leamon
Published 2005 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The folate receptor (FR) is a valuable therapeutic target that is highly expressed on a variety of cancers. The current development of folate-targeted cancer therapies has created the need for quantitating functional FRs in clinical specimens. In this article, we report on the creation of a highly sensitive radioactive binding method for quantitatively measuring FR expression in frozen tissue homogenates. Expression was positive in approximately 89% of human ovarian carcinomas but was negligible in both mucinous ovarian carcinomas and normal ovary. Expression was also significant in carcinomas of the kidney, endometrium, lung, breast, bladder, and pancreas. Normal tissues from humans and six different laboratory species were also analyzed; surprisingly, some interspecies variability in FR expression (especially in kidney, spleen, and lung tissue) was found. Interestingly, normal human lung tissue displayed high expression levels, whereas expression in normal lung of the other species was negligible. However, considering that folate-drug conjugates fail to accumulate in the lungs of patients, the consequence of this finding was not considered to be of clinical concern. Overall, this new methodology is reliable for determining functional FR expression levels in tissues, and it could possibly be a useful clinical test to determine patient candidacy for FR-targeted therapeutics.
This paper references
10.1093/JN/127.6.1137
Folate transport proteins mediate the bidirectional transport of 5-methyltetrahydrofolate in cultured human proximal tubule cells.
K. M. Morshed (1997)
10.1152/AJPCELL.1993.264.2.C302
Internalization and intracellular transport of folate-binding protein in rat kidney proximal tubule.
H. Birn (1993)
10.1152/AJPCELL.2000.278.4.C812
Folate deficiency reduces the GPI-anchored folate-binding protein in rat renal tubules.
M. da Costa (2000)
10.1152/AJPRENAL.1997.272.1.F70
Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule.
H. Birn (1997)
10.1177/030089168907500524
Immunohistochemical Reactivity of a Monoclonal Antibody Prepared against Human Ovarian Carcinoma on Normal and Pathological Female Genital Tissues
R. Veggian (1989)
10.1016/0016-5085(90)90614-7
Folic acid transport in organ-cultured mucosa of human intestine. Evidence for distinct carriers.
J. Zimmerman (1990)
10.1007/s00262-002-0266-6
Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors
Y. Lu (2002)
10.1111/j.1699-0463.1995.tb01420.x
Folate receptor in malignant effusions of ovarian carcinoma
J. Holm (1995)
10.1172/JCI113469
Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells.
M. Kane (1988)
Isolation and characterization of a folate receptor from human placenta.
A. Antony (1981)
10.1042/BJ2800267
High-affinity folate binding in human choroid plexus. Characterization of radioligand binding, immunoreactivity, molecular heterogeneity and hydrophobic domain of the binding protein.
J. Holm (1991)
Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles.
B. Kamen (1988)
10.1007/BF01872839
Mediated uptake of folate by a high-affinity binding protein in sublines of L1210 cells adapted to nanomolar concentrations of folate
G. Henderson (2005)
10.1021/BC0200430
Synthesis and Biological Evaluation of EC20: A New Folate-Derived, 99mTc-Based Radiopharmaceutical
C. P. Leamon (2002)
10.1002/IJC.2910570719
New anti‐lung‐cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma
Wilbur A. Franklin (1994)
The isolation, characterization, and comparison of the membrane-associated and soluble folate-binding proteins from human KB cells.
P. C. Elwood (1986)
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.
S. Weitman (1992)
10.1038/KI.1992.7
A high-affinity folate binding protein in proximal tubule cells of human kidney.
J. Holm (1992)
10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S
Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications
J. Ross (1994)
10.1615/CRITREVTHERDRUGCARRIERSYST.V15.I6.20
Folate-mediated targeting of therapeutic and imaging agents to cancers.
J. Reddy (1998)
10.1111/j.1699-0463.1994.tb04892.x
Folate receptor of human mammary adenocarcinoma
J. Holm (1994)
10.1016/J.ADDR.2004.01.008
Folate-targeted chemotherapy.
C. P. Leamon (2004)
Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.
L. Coney (1991)
Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.
P. Garinchesa (1993)
10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F
Overexpression of folate binding protein in ovarian cancers
G. Toffoli (1997)
10.1387/IJDB.8507562
Epithelial-stromal interactions in colon cancer.
F. T. Bosman (1993)
10.1016/0003-9861(86)90705-8
The isolation and properties of multiple forms of folate binding protein in cultured KB cells.
C. Luhrs (1986)
10.1016/J.ADDR.2004.02.003
Folate receptor-targeted drugs for cancer and inflammatory diseases.
P. Low (2004)
Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography.
P. Y. Li (1996)
10.1182/BLOOD.V93.11.3940.411K09_3940_3948
Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells.
J. Reddy (1999)
Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical.
C. Mathias (1998)
10.1016/0959-8049(94)90257-7
Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19.
L. Mantovani (1994)
10.1002/IJC.2910390306
Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity
S. Miotti (1987)
10.1016/S1359-6446(00)01594-4
Folate-mediated targeting: from diagnostics to drug and gene delivery.
C. P. Leamon (2001)
10.1023/A:1027313502270
Folate Receptors in Malignant and Benign Tissues of Human Female Genital Tract
J. Holm (1997)
10.1067/MTC.2001.111176
The α folate receptor is highly activated in malignant pleural mesothelioma
R. Bueno (2001)



This paper is referenced by
Therapeutics , Targets , and Chemical Biology Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer
D. Dhawan (2013)
10.1517/17425240903427940
Liposomal cancer therapy: exploiting tumor characteristics
T. Kaasgaard (2010)
10.1016/B978-012369448-5.50012-4
Targeting thymidylate synthase by antifolate drugs for the treatment of cancer
A. Jackman (2008)
10.1371/journal.pone.0006292
Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients
E. Basal (2009)
10.1016/j.colsurfb.2010.02.023
A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: in vitro evaluation.
Nam Muk Oh (2010)
A Multi-Scale Hybrid Nanoparticle Platform with Controlled Cellular Interaction and Targeting Kinetics
Suhair Sunoqrot (2013)
10.1007/978-1-4419-7216-3_12
Potential for α-Folate Receptor-Targeted Treatment for Ovarian Cancer
C. H. Ng (2011)
10.1517/17425247.2011.547934
Cellular interactions of therapeutically delivered nanoparticles
A. Kumari (2011)
10.21037/TLCR.2016.10.07
Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.
D. Pérez-Callejo (2016)
An special epithelial staining agents: folic acid receptor-mediated diagnosis (FRD) effectively and conveniently screen patients with cervical cancer.
Meng-Han Lu (2015)
Novel Antibody-Targeted Liposomes for the Treatment of Solid Tumors
Michiel Bolkestein (2016)
10.1007/978-1-4939-9220-1
RNA Interference and Cancer Therapy
Lekha Dinesh Kumar (2019)
Magnetic Nanosensors For Multiplexed Bacterial Pathogenesis Identification
Charalambos Kaittanis (2010)
10.4233/UUID:B46CC724-C6CF-4282-B3BA-3817E8BEBF87
Synthetic biology meets liposome-based drug delivery
A. S. Canton (2019)
10.1097/CJI.0000000000000029
A Phase I/Ib Study of Folate Immune (EC90 Vaccine Administered With GPI-0100 Adjuvant Followed by EC17) With Interferon-&agr; and Interleukin-2 in Patients With Renal Cell Carcinoma
R. Amato (2014)
HUMAN ENDOGENOUS RETROVIRUS K AS A NOVEL TUMOR-ASSOCIATED ANTIGEN FOR DEVELOPMENT OF AN OVARIAN CANCER VACCINE
K. Rycaj (2012)
10.1111/j.1749-6632.2009.04977.x
Ligand‐Targeted Delivery of Small Interfering RNAs to Malignant Cells and Tissues
M. Thomas (2009)
10.2147/IJN.S110689
Folate-conjugated boron nitride nanospheres for targeted delivery of anticancer drugs
S. Feng (2016)
10.1038/s41467-020-16838-w
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
M. Geiger (2020)
10.1007/s00259-020-05054-9
Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model
P. Guzik (2020)
10.1109/ULTSYM.2017.8092693
Acoustic response of targeted nanodroplets post-activation using high frame rate imaging
Ge Zhang (2017)
10.1007/978-3-030-12780-0_19
Use of Carbonic Anhydrase IX Inhibitors for Selective Delivery of Attached Drugs to Solid Tumors
S. Gardeen (2019)
10.1007/s12274-018-2032-x
A novel tumor-targeting treatment strategy uses energy restriction via co-delivery of albendazole and nanosilver
Jianming Liang (2018)
10.1007/978-3-030-29168-6_14
Folate Receptor and Targeting Strategies
Bhagyashri Joshi (2019)
10.1038/nrd4519
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
M. Srinivasarao (2015)
10.1007/978-1-4614-7876-8_13
Heterogeneity of Cancers and Its Implication for Targeted Drug Delivery
T. A. Denison (2013)
10.1039/c7cs00152e
Platinum nanoparticles in nanobiomedicine.
Deborah Pedone (2017)
10.7150/thno.9423
Co-delivery of Doxorubicin and Bmi1 siRNA by Folate Receptor Targeted Liposomes Exhibits Enhanced Anti-Tumor Effects in vitro and in vivo
Tan Yang (2014)
10.18632/oncotarget.16841
Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma
L. Cai (2017)
10.1155/2017/2069685
Folate-Functionalized Mesoporous Silica Nanoparticles as a Liver Tumor-Targeted Drug Delivery System to Improve the Antitumor Effect of Paclitaxel
X. Xu (2017)
10.1038/modpathol.2011.82
Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance
M. D'angelica (2011)
10.1007/s00280-009-1132-4
Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models
A. Gabizon (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar